FGFR2 and intrahepatic cholangiocarcinoma: Genomic alterations (including mutation, fusion, and rearrangement) that activate fibroblast growth factor receptor 2 (FGFR2) are almost exclusively found in patients with ICC, making it a promising therapeutic target [358, 359].